Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination With Chemotherapy

NCT05101551 is registered in ClinicalTrials.gov with Norman J. Lacayo as lead sponsor.

NCT NCT05101551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05101551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination With Chemotherapy
Lead sponsor
Norman J. Lacayo
Phase
Phase 1
Overall status
Recruiting
Start date
February 23, 2023
Completion date
April 30, 2027
Enrollment
34 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia